Domestic pharmaceutical firms eye price hike of OTC products

Published: 2011-11-07 06:59:00

Updated: 2011-11-07 06:59:00

Korean drug firms are considering a price hike of their flagship over-the-counter (OTC) drugs as they are by concerned by the potentially significant impact of the government’s new drug pricing reform on the prices and profit margin of their products, industry sources said recently.

The govern...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK